Hints and tips:
Related Special Reports
...Soriot already earns more than bosses of larger European pharmaceutical companies....
...Soriot’s new pay deal comes after the company hit a $45bn sales target in 2023 that the chief executive had set in 2014 when the company fended off a takeover bid from US rival Pfizer....
...AstraZeneca’s chair has hit out at proxy advisers for “double standards” that “do serious harm” to the competitiveness of UK companies, after more than a third of the company’s shareholders voted against...
...The company has struggled with its own supply issues....
...No concessions of liability have been made,” the company said....
...company’s biggest-selling drugs....
...The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for...
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...GSK has sued Pfizer and BioNTech, alleging that their pharmaceutical rivals’ Covid-19 vaccine infringed “revolutionary” mRNA patents the British company filed in 2010....
...The company repeated its guidance of double-digit growth in sales and earnings for the current year....
...Emblaveo was developed in partnership with US pharma company AbbVie and with financial support from US and EU public bodies....
...Clarifying which companies are responsible for innovations will be “even more important” as pharma companies explore uses for mRNA in cancer, autoimmune diseases and other viruses, said Anna Wolters-Höhne...
...“The big issue we have is that our member companies, in order to bring active ingredients and finished drug products from China to the EU, need certification from certain authorities,” Bicane said....
...The Swiss pharmaceutical company reported sales of SFr14.4bn ($15.8bn), in line with analysts’ estimates, with eye medicine Vabysmo proving the company’s “biggest growth driver”....
...Following the dividend raise, shares in the company closed 2.3 per cent higher on Thursday....
...This means the German company is the sole supplier of a treatment that has become a standard of care in recent years....
...These shifts have led some companies to remove the UK from their supply chains....
...Fuel pump prices are not falling in line with wholesale prices, the Competition and Markets Authority said on Thursday, prompting concerns that competition is not working well among UK retailers....
...Novo Nordisk purchased Dicerna Pharmaceuticals, a company focused in RNA-based therapeutics, for $3.3bn in 2021....
...In a statement on Thursday, the UK-based pharmaceutical company said that it would pay a $3.10-per-share dividend for 2024, 20 cents above the 2023 payout, “underlining the company’s confidence in its performance...
...by Swiss company Novartis....
...“More recent trends give cause for concern that competition is still not working well in this market to hold down pump prices,” she added....
...The company’s immunotherapy drug Imfinzi helped patients with so-called limited stage small cell lung cancer survive for longer....
...Soaring sales of the products have pushed the companies’ valuations to record highs....
...The company will increase its footprint at a Cambridge biomedical site and build a vaccine manufacturing site in Speke in Liverpool....
International Edition